Stopping the Clock on Seizures!

Xiaoqin Fu1, Judy S Liu2, Peijun Li1

  • 1The Second Affiliated Hospital and Yuying Children's Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China.

Insights

REV-ERBα, a regulator of the circadian clock, promotes seizures by affecting GABA signaling. This suggests targeting REV-ERBα could be a new epilepsy treatment strategy.

Area of Science:

  • Neuroscience
  • Chronobiology
  • Epilepsy Research

Background:

  • The circadian molecular clock regulates numerous physiological processes.
  • Disruptions in circadian rhythms are implicated in various neurological disorders, including epilepsy.
  • The specific role of circadian regulators in seizure susceptibility remains incompletely understood.

Purpose of the Study:

  • To investigate the role of REV-ERBα, a core component of the circadian clock, in seizure activity.
  • To determine the molecular mechanisms by which REV-ERBα influences neuronal excitability and GABAergic signaling.
  • To evaluate REV-ERBα as a potential therapeutic target for epilepsy.

Main Methods:

  • Utilized molecular biology techniques to assess REV-ERBα expression and function.
  • Employed electrophysiological methods to study GABA signaling in the presence of altered REV-ERBα activity.
  • Investigated the effects of modulating REV-ERBα on seizure thresholds in relevant models.

Main Results:

  • Zhang et al. demonstrated that REV-ERBα acts as a pro-convulsant factor.
  • REV-ERBα was shown to negatively impact GABA signaling, a key inhibitory neurotransmitter system.
  • Modulation of REV-ERBα activity directly influenced seizure susceptibility.

Conclusions:

  • REV-ERBα plays a significant role in regulating seizure threshold.
  • The findings highlight the involvement of the circadian molecular clock in the pathophysiology of epilepsy.
  • REV-ERBα emerges as a promising therapeutic target for developing novel anti-seizure medications.

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
645
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
1.2K
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
888
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
572
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
818
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
645